Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis
US8257697B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Oct 31, 2008 |
| Grant date | Sep 4, 2012 |
| Priority date | — |
| Expiry date | Sep 22, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for determining a patient's susceptibility to anaphylaxis comprises assaying the activity of platelet activating factor acetylhydrolase (PAF-AH) activity and comparing the measured activity to a reference value, wherein the level of PAF-AH activity inversely correlates with the susceptibility to anaphylaxis. The method further comprises determining the severity of anaphylaxis by correlating the degree of reduced PAF-AH activity to the reference value. The method further comprises measuring IgE concentration and comparing the measured concentration to a reference concentration. The invention further provides a method for diagnosing anaphylaxis in a patient comprising measuring the serum concentration of platelet activating factor (PAF) and comparing the measured concentration to a reference value, wherein the concentration of PAF correlates directly with severity of anaphylaxis. The invention also provides a kit for performing the required assay or assays.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.